SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-20-019460
Filing Date
2020-09-09
Accepted
2020-09-09 09:30:16
Documents
6
Period of Report
2020-09-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20200908_8k.htm 8-K 40927
2 EXHIBIT 10.1 ex_203274.htm EX-10.1 29006
3 EXHIBIT 10.2 ex_203251.htm EX-10.2 119934
4 EXHIBIT 99.1 ex_203252.htm EX-99.1 14306
5 image01.jpg GRAPHIC 5890
6 logo02.gif GRAPHIC 4839
  Complete submission text file 0001437749-20-019460.txt   220777
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 201165714
SIC: 2834 Pharmaceutical Preparations